Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder

Current Psychiatry Reports

Volumn 12, Issue 2, 2010, Pages 111-115

  Yu, Zheya Jenny ^a   Parker Kotler, Caroline ^b   Tran, Kathleen ^c   Weller, Ronald A ^d   Weller, Elizabeth B ^d  

^a PENNSYLVANIA HOSPITAL   (United States)

^b Greentree Pediatrics   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Psychostimulants; Vasculopathy

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; DEXMETHYLPHENIDATE; LAMOTRIGINE; METHYLPHENIDATE; OXCARBAZEPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE;

ADD ON THERAPY; ADOLESCENT; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CASE REPORT; CHILD; DRUG DOSE INCREASE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PERIPHERAL VASCULAR DISEASE; PHLEBOGRAPHY; RAYNAUD PHENOMENON; REVIEW; SCHOOL CHILD; TACHYCARDIA; TREATMENT DURATION;

ADOLESCENT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; MALE; METHYLPHENIDATE; PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953538419     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0093-y     Document Type: Review

References (12)

1. Guevara J, Lozano P, Wickizer T, et al.: Psychotropic medication use in a population of children who have attention-deficit/ hyperactivity disorder. Pediatrics 2002, 109:733-739.
2. Sadeghian H: Lacunar stroke associated with methylphenidate abuse. Can J Neurol Sci 2004, 31:109-111.
3. Thai DL, Yurasists LN, Rudolph GR, et al.: Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. Drug Metab Dispos 1999, 27:645-650.
4. Stahl SM: Essential psychopharmacology, neuroscientific basis and practical applications. In Cognitive Enhancers, edn 2. Edited by Stahl SM. Cambridge, United Kingdom: Cambridge University Press; 2004:461-466.
5. Dulcan MK, Lizarralde C: Helping parents, youth, and teachers understand medications for behavioral and emotional problems: a resource book of medication information handouts. In Stimulants, edn 2. Edited by Dulcan MK, Lizarralde C. Washington, DC: American Psychiatric Publishing; 2003:75-80.
6. Kokkinos J, Levine SR: Possible association of ischemic stroke with phentamine. Stroke 1993, 24:310-313.
7. Jefferson HJ, Jayne DR: Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant 1999, 14:1761-1763.
8. Leithauser B, Langheinrich AC, Rau WS, et al.: A 22-year-old woman with lower limb arteriopathy. Buerger's disease, or methamphentamine- or cannabis-induced arteritis? Heart Vessels 2005, 20:39-43.
9. Bingham C, Beaman M, Nicholls AJ, Anthony PP: Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Transplant 1998, 13:2654-2655.
10. Syed R, Moore T: Methylphenidate and dextroamphetamineinduced peripheral vasculopathy. J Clin Rheumatol 2008, 14:30-33. This was a case report of four patients treated with MPH (n = 2) or dextroamphetamine (n = 2) presenting with acral cyanosis, livedo reticularis, or RS potentially contributing to vasculopathy.
11. GoldmanW, Seltzer R, Reuman P: Association between treatment with central nervous system stimulants and Raynaud's syndrome in children. Arthritis Rheum 2008, 58:563-566. This was a retrospective case-control study of pediatric rheumatology patients (with and without RS) that examined the association between development of RS and CNS stimulants used to treat ADHD.
12. Sule SD, Wigley FM: Current rheumatology: diagnosis and treatment. In Raynaud Phenomenon. Edited by Imboden J, Hellmann DB, Stone JH. Columbus, OH: McGraw-Hill; 2004:183-185.